Walk into almost any dental office, med spa, or veterinary clinic today, and there’s a good chance someone at the front desk will ask a version of the same question: “Would you like to pay over time?”
This issue is at the center of a rapidly expanding part of consumer finance. Elective and out-of-pocket medical care can be costly, and insurance often does not cover it. The American Dental Association’s Health Policy Institute has repeatedly found that cost is the main reason adults avoid dental care. At the same time, more people are seeking elective procedures. The American Society of Plastic Surgeons said that the number of cosmetic procedures increased by 7% in 2025.
Financing has stepped into that gap. According to a 2023 report from the Consumer Financial Protection Bureau (CFPB), patients used medical credit cards and deferred-interest loans to pay for almost $23 billion in healthcare expenses across more than 17 million purchases between 2018 and 2020. And that figure covers only one slice of the market.
This article explains how point-of-care patient financing works, who pays whom, and how the companies behind it make money.
What is point-of-care patient financing? How does it work?
Point-of-care financing lets a patient apply for a loan or payment plan when they agree to treatment, usually through a tablet at the front desk, a text link, or a QR code. If approved, the patient pays over weeks, months, or years, and the provider gets paid upfront.
The patient side.
The patient fills out a short application, receives a decision within minutes, and chooses a plan. Plans range from short interest-free installments to multiyear loans with interest. Some products are revolving credit cards that can be reused across visits. Others are fixed installment loans tied to a single treatment.
The provider side.
The practice signs up with a financing platform, trains its front-desk team to offer it, and receives the treatment cost, minus a fee, within a few business days. In most models, the practice doesn’t carry the risk if the patient later stops paying.
The lender side.
Behind the platform sits the capital that actually funds the loans. Many patient financing companies aren’t banks. They partner with chartered banks that originate the loans and rely on credit facilities from banks or investors to fund their operations.
Consider Cherry, a San Francisco company founded in 2019 that serves dental, medical aesthetics, veterinary,y and other practices. Cherry describes itself as a financial technology platform rather than a lender and says Lead Bank originates the loans made through it. Cherry may then purchase interests in or service those loans. In 2022, Cross River’s Strategic Direct Lending Group extended a $50 million credit facility to the company, with Cross River also originating loans through its platform at the time.
That structure—a tech company at the front, a bank in the middle, and outside capital behind it—is common across the industry.
What is the business model of patient financing? How do these companies make money?
Value proposition
For patients, payment plans offer predictable payments that help make large bills easier to handle. You can also get a quick decision without having to leave the office. Some providers use soft credit checks at the application stage, so your credit score won’t be affected.
For providers, payment plans can lead to more patients accepting treatment, faster payments, and less time spent following up on balances. Patients who might delay a $4,000 procedure are more likely to say yes to a monthly payment plan. Practices also avoid the hassle of managing their own payment plans, which can tie up cash and staff time.
Revenue model
Patient financing companies generally earn money from three sources.
Merchant fees. Providers pay a percentage of each financed transaction. This is usually their main source of revenue, especially for interest-free plans where patients do not pay extra. Fees can vary a lot depending on the company and the length of the plan.
For perspective, a 2026 Federal Reserve analysis found that buy now, pay later merchant fees are usually between 5% and 8%, while credit card fees are typically 2% to 3%.
Consumer interest. On longer or higher-risk plans, patients pay interest. Rates span a wide range. Cherry’s disclosures list APRs from 0% to 35.99%. The CFPB found that medical credit cards and installment loans in its review carried rates around 26.99%, versus about 16% for traditional credit cards at the time.
Loan economics and servicing. When a platform purchases interests in the loans it helps originate, it earns the spread between what borrowers pay and what its capital costs. Servicing fees and late fees can add to that, although many newer players market themselves on low or no late fees.
The deferred interest divide
The industry splits into two broad models.
Healthcare credit cards often use deferred interest. Patients pay no interest if they clear the balance by the end of a promotional period, but if they don’t, interest is charged retroactively from the purchase date. The CFPB found that patients paid about $1 billion in deferred interest between 2018 and 2020.
Fixed installment lenders take a different approach. They charge either 0% or a stated APR from the start, with no retroactive interest. This model has become a key selling point for newer entrants competing against established card programs.
Key risks in the patient financing model
Credit risk. High approval rates help practices convert more patients, but approving more borrowers with weaker credit raises the risk of losses. Pricing that risk correctly is the business’s central challenge.
Funding costs. Because most platforms rely on bank partners and credit facilities, rising interest rates squeeze margins, especially on 0% plans where revenue comes only from merchant fees.
Regulation. The CFPB’s 2023 report criticized how some medical credit products were marketed in provider offices. Federal oversight of buy now, pay later loosened in 2025 when the CFPB moved to withdraw a 2024 interpretive rule, but states have started acting on their own. New York, for example, now requires nonbank BNPL lenders to be licensed.
Provider trust. Front-desk staff are the industry’s real sales force. If patients feel pressured or confused by terms, practices take the reputational hit, and the CFPB has warned that some providers lacked the training to explain complex terms like deferred interest.
The strategic takeaway
Point-of-care financing works because it solves problems for both sides of the counter. Patients get a way to say yes to care they want or need, and practices get paid faster without becoming lenders themselves. The companies in the middle make money by sitting at that moment of decision, collecting fees from providers and interest from some borrowers, while managing credit risk with capital from banks and investors.
The winners in this market will likely be the ones that keep approval rates high without letting losses spiral, keep merchant fees competitive, and make their terms simple enough for patients to trust.
Sources: CFPB, “Medical Credit Cards and Financing Plans” (May 2023); Federal Reserve FEDS Note, “Buy Now, Pay Later Beyond ‘Pay in 4′” (June 2026); ASPS 2025 Procedural Statistics Report; ADA Health Policy Institute; Cherry company disclosures and financing partners page; Cross River press release (March 2022).


